Related Experiment Video
Updated: May 22, 2026
07:40
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
Challenges in drug and biomarker co-development
1ST-Consulting, Bethesda, MD, USA. setaube@aol.com
Summary
Co-developing drugs and biomarkers is crucial when they are closely linked. Early planning and a multidisciplinary team are essential to navigate the risks, benefits, and challenges of this integrated approach.
Area of Science:
- Biopharmaceutical development
- Biomarker discovery and validation
- Clinical trial design
Background:
- Biomarkers are increasingly integral to drug development.
- Co-development strategies offer potential benefits but require careful consideration.
- Early-stage planning is critical for successful integrated drug and biomarker development.
Purpose of the Study:
- To define the appropriate circumstances for drug and biomarker co-development.
- To discuss key challenges and considerations in the co-development process.
- To emphasize the importance of early strategic planning and team assembly.
Main Methods:
- Review of existing literature and best practices in drug and biomarker co-development.
- Analysis of challenges including assay type determination (LDT, reference lab, kit).
- Examination of clinical trial designs for evaluating biomarker utility and regulatory pathways.
Main Results:
- Co-development is most appropriate when biomarkers are intricately linked to drug use.
- Key challenges involve assay selection, trial design for clinical utility, and regulatory navigation.
- Successful co-development necessitates early, proactive planning and a multidisciplinary team.
Conclusions:
- Strategic co-development of drugs and biomarkers requires careful risk-benefit analysis early in the process.
- Addressing challenges in assay development, trial design, and regulatory strategy is vital for success.
- Early integration of multidisciplinary expertise is paramount for effective drug and biomarker co-development.
Related Concept Videos
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...